Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.

In this study, a panel of normal human prostate cells (HPCs) and tumor cells derived from metastases were studied by (1)H NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of choline compounds. Although an elevated choline signal has been observed previously in clinical studies, the contribution of the different Cho compounds to this elevation, as well as their quantification, has not been established until now. Here we have shown that HPCs derived from metastases exhibit significantly higher phosphocholine as well as glycerophosphocholine levels compared with normal prostate epithelial and stromal cells. Thus the elevation of the choline peak observed clinically in prostate cancer is attributable to an alteration of phospholipid metabolism and not simply to increased cell density, doubling time, or other nonspecific effects. Androgen deprivation of the androgen receptor-positive cell lines resulted in a significant increase of choline compounds after chronic androgen deprivation of the LNCaP cell line and in a decrease of choline compounds after a more acute androgen deprivation of the LAPC-4 cell line. These data strongly support the use of proton magnetic resonance spectroscopic imaging to detect the presence of prostate cancer for diagnosis, to detect response subsequent to androgen ablation therapy, and to detect recurrence.

[1]  中神 克尚 Increased choline Kinase activity and elevated phosphocholine levels in human colon cancer , 2000 .

[2]  C. Cordon-Cardo,et al.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.

[3]  T. Hara,et al.  Positron emission tomography of esophageal carcinoma using 11C‐choline and 18F‐fluorodeoxyglucose , 1999 .

[4]  H. Schmid,et al.  Diagnosis and Staging of Prostatic Carcinoma: What Is Really Necessary? , 1999, Urologia Internationalis.

[5]  N. Kosaka,et al.  Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. , 1999, Cancer.

[6]  F. Podo Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[7]  R. Pankov,et al.  Ha‐ ras‐TRANSFORMATION ALTERS THE METABOLISM OF PHOSPHATIDYLETHANOLAMINE AND PHOSPHATIDYLCHOLINE IN NIH 3T3 FIBROBLASTS , 1999, Cell biology international.

[8]  J. Nelson,et al.  Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines , 1999, The Prostate.

[9]  Zeng-chen Ma,et al.  Microvessel density of hepatocellular carcinoma: its relationship with prognosis , 1999, Journal of Cancer Research and Clinical Oncology.

[10]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[11]  S. Hayward,et al.  The role of stroma in prostatic carcinogenesis , 1998 .

[12]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  T. Nevalainen,et al.  Group II phospholipase A2 in human male reproductive organs and genital tumors , 1998, The Prostate.

[14]  J. Lacal,et al.  Choline kinase inhibitors as a novel approach for antiproliferative drug design , 1997, Oncogene.

[15]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[16]  S. Williams,et al.  Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.

[17]  P. Carroll,et al.  Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.

[18]  F. Faas,et al.  Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. , 1996, The Journal of urology.

[19]  H. Degani,et al.  Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. , 1996, Anticancer research.

[20]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[21]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[22]  C. Kent,et al.  Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. , 1995, Archives of biochemistry and biophysics.

[23]  R. Gillies,et al.  Increase of GPC Levels in Cultured Mammalian Cells during Acidosis. A 31P MR Spectroscopy Study Using a Continuous Bioreactor System , 1995, Magnetic resonance in medicine.

[24]  J Kurhanewicz,et al.  Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. , 1995, Urology.

[25]  M. A. Samphilipo,et al.  Quantitative proton spectroscopy of canine brain: in Vivo and in Vitro correlations , 1994, Magnetic resonance in medicine.

[26]  T. Chen,et al.  Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. , 1993, Cytogenetics and cell genetics.

[27]  J. Kurhanewicz,et al.  Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study , 1993, Magnetic resonance in medicine.

[28]  G. Jenster,et al.  The human androgen receptor: Structure/function relationship in normal and pathological situations , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  J. Trapman,et al.  Androgen receptor abnormalities , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  A. Brothman,et al.  Metastatic properties of the human prostatic cell line, PPC-1, in athymic nude mice. , 1991, The Journal of urology.

[31]  R. Dahiya,et al.  Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer. , 1991, Biomedica biochimica acta.

[32]  C. Kent,et al.  Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. , 1990, The Journal of biological chemistry.

[33]  George L. Wright,et al.  Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma , 1989, International journal of cancer.

[34]  I. Kondo,et al.  Establishment of a new prostatic carcinoma cell line (TSU-Pr1). , 1987, The Journal of urology.

[35]  J. Horoszewicz,et al.  A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). , 1984, Cancer genetics and cytogenetics.

[36]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[37]  J. Lechner,et al.  Chromosomal analysis of human prostatic adenocarcinoma cell lines. , 1980, Cancer research.

[38]  S. Arya,et al.  The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.

[39]  D. Paulson,et al.  Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. , 1980, Progress in clinical and biological research.

[40]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[41]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[42]  R. Vollmer,et al.  Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. , 1977, Cancer research.